IL129612A - Pharmaceutical compositions comprising adamantane amines - Google Patents

Pharmaceutical compositions comprising adamantane amines

Info

Publication number
IL129612A
IL129612A IL12961297A IL12961297A IL129612A IL 129612 A IL129612 A IL 129612A IL 12961297 A IL12961297 A IL 12961297A IL 12961297 A IL12961297 A IL 12961297A IL 129612 A IL129612 A IL 129612A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
adamantane amines
adamantane
amines
disease virus
Prior art date
Application number
IL12961297A
Other languages
English (en)
Other versions
IL129612A0 (en
Original Assignee
Hanns Ludwig
Detlef Dietrich
Hinderk M Emrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanns Ludwig, Detlef Dietrich, Hinderk M Emrich filed Critical Hanns Ludwig
Publication of IL129612A0 publication Critical patent/IL129612A0/xx
Publication of IL129612A publication Critical patent/IL129612A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12961297A 1996-10-30 1997-10-23 Pharmaceutical compositions comprising adamantane amines IL129612A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19644998A DE19644998C1 (de) 1996-10-30 1996-10-30 Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
DE9704255 1997-10-23

Publications (2)

Publication Number Publication Date
IL129612A0 IL129612A0 (en) 2000-02-29
IL129612A true IL129612A (en) 2003-02-12

Family

ID=7810348

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12961297A IL129612A (en) 1996-10-30 1997-10-23 Pharmaceutical compositions comprising adamantane amines

Country Status (16)

Country Link
US (1) US6384083B1 (cs)
EP (1) EP0935461B1 (cs)
JP (1) JP4290764B2 (cs)
CN (1) CN1133425C (cs)
AT (1) ATE245975T1 (cs)
AU (1) AU722505B2 (cs)
BR (1) BR9712466A (cs)
CA (1) CA2306830C (cs)
CZ (1) CZ148999A3 (cs)
DE (2) DE19644998C1 (cs)
DK (1) DK0935461T3 (cs)
ES (1) ES2207751T3 (cs)
HU (1) HUP0000386A3 (cs)
IL (1) IL129612A (cs)
PL (1) PL189608B1 (cs)
WO (1) WO1998018457A1 (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2005019166A2 (en) * 2003-06-11 2005-03-03 Neuromolecular, Inc. Method of targeting a therapeutic agent
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
US8393169B2 (en) 2007-09-19 2013-03-12 Emerson Climate Technologies, Inc. Refrigeration monitoring system and method
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
US8835507B2 (en) * 2012-02-21 2014-09-16 Vymed Corporation Adamantane derivatives possessing anti-viral and anti-microbial activity
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
DE102018009721A1 (de) 2017-12-29 2019-07-04 Euroimmun Medizinische Labordiagnostika Ag Verfahren zur Diagnose einer Bornavirus-Infektion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6482M (cs) * 1916-09-20 1968-11-25
DE2224539A1 (de) * 1972-05-19 1973-12-06 Merz & Co Aminoadamantanverbindungen und verfahren zu ihrer herstellung
US4174407A (en) * 1978-01-13 1979-11-13 Sumitomo Chemical Company, Limited Antiviral agent
US4148896A (en) * 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
US4174047A (en) * 1978-03-06 1979-11-13 3-in-1, Inc. Vending machine for newspapers and the like
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5576355A (en) * 1993-06-04 1996-11-19 Mobil Oil Corp. Diamondoid derivatives for pharmaceutical use
DE19510189A1 (de) * 1995-03-21 1996-09-26 Hartmut Dr Goebel Verwendung von Amantadin

Also Published As

Publication number Publication date
DE19644998C1 (de) 1998-06-10
US6384083B1 (en) 2002-05-07
WO1998018457A1 (de) 1998-05-07
AU5116298A (en) 1998-05-22
BR9712466A (pt) 1999-12-21
EP0935461B1 (de) 2003-07-30
HUP0000386A3 (en) 2001-04-28
AU722505B2 (en) 2000-08-03
JP4290764B2 (ja) 2009-07-08
EP0935461A1 (de) 1999-08-18
ATE245975T1 (de) 2003-08-15
DE59710517D1 (de) 2003-09-04
ES2207751T3 (es) 2004-06-01
CZ148999A3 (cs) 1999-11-17
IL129612A0 (en) 2000-02-29
PL189608B1 (pl) 2005-08-31
JP2001502701A (ja) 2001-02-27
PL333059A1 (en) 1999-11-08
CN1235540A (zh) 1999-11-17
CA2306830A1 (en) 1998-05-07
DK0935461T3 (da) 2003-11-24
CA2306830C (en) 2008-07-08
CN1133425C (zh) 2004-01-07
HUP0000386A1 (hu) 2000-12-28

Similar Documents

Publication Publication Date Title
IL129612A (en) Pharmaceutical compositions comprising adamantane amines
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
NO961326D0 (no) Inhibitorer av
HUP0004170A2 (hu) Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BG101118A (en) Therapeutical compounds
BR9710372A (pt) Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase
CA2293470A1 (en) Benzimidazole derivatives
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
ATE245977T1 (de) Therapeutische substituierte guanidine
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
MX9805441A (es) Compuestos terapeuticos.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
KR960000248A (ko) 골대사 질환 치료제
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
MM9K Patent not in force due to non-payment of renewal fees